- 中文名稱
AKT1 一抗
- 英文名字
- AKT1 Primary antibody
- 供應商
- Promab
- 產品貨號
- PMB-P06974
- 產品報價
- ¥詢價/100ul

- 產品說明書
- 點擊查看
- 購買方式
- Promab中國區現貨中心已經建立,95%產品中國有現貨庫存。銀行轉賬、電匯、支票、現金,在線支付寶及網銀支付,或直接與我們電話聯系。本公司所有產品僅供科研使用,不用于臨床診斷。
- 產品新聞

- 背景資料
- This gene encodes one of the three members of the human AKT serine-threonine protein kinase family which are often referred to as protein kinase B alpha, beta, and gamma. These highly similar AKT proteins all have an N-terminal pleckstrin homology domain, a serine/threonine-specific kinase domain and a C-terminal regulatory domain. These proteins are phosphorylated by phosphoinositide 3-kinase (PI3K). AKT/PI3K forms a key component of many signalling pathways that involve the binding of membrane-bound ligands such as receptor tyrosine kinases, G-protein coupled receptors, and integrin-linked kinase. These AKT proteins therefore regulate a wide variety of cellular functions including cell proliferation, survival, metabolism, and angiogenesis in both normal and malignant cells. AKT proteins are recruited to the cell membrane by phosphatidylinositol 3,4,5-trisphosphate (PIP3) after phosphorylation of phosphatidylinositol 4,5-bisphosphate (PIP2) by PI3K. Subsequent phosphorylation of both threonine residue 308 and serine residue 473 is required for full activation of the AKT1 protein encoded by this gene. Phosphorylation of additional residues also occurs, for example, in response to insulin growth factor-1 and epidermal growth factor. Protein phosphatases act as negative regulators of AKT proteins by dephosphorylating AKT or PIP3. The PI3K/AKT signalling pathway is crucial for tumor cell survival. Survival factors can suppress apoptosis in a transcription-independent manner by activating AKT1 which then phosphorylates and inactivates components of the apoptotic machinery. AKT proteins also participate in the mammalian target of rapamycin (mTOR) signalling pathway which controls the assembly of the eukaryotic translation initiation factor 4F (eIF4E) complex and this pathway, in addition to responding to extracellular signals from growth factors and cytokines, is disregulated in many cancers. Mutations in this gene are associated with multiple types of cancer and excessive tissue growth including Proteus syndrome and Cowden syndrome 6, and breast, colorectal, and ovarian cancers. Multiple alternatively spliced transcript variants have been found for this gene.
- 應用類型
- IHC
- 免疫原
- Fusion protein of human AKT1
- 來源宿主
- Rabbit
- 反應性
- Human, Mouse, Rat
- 保存建議
- 4℃短期保存;-20℃長期保存。避免凍融循環。
- 其他
- ProMab 生物技術公司通過整合生物信息學、分子生物學、蛋白質表達、純化技術、基因克隆、微生物學和免疫學,利用新型高通量技術開發重組蛋白、抗體和工程細胞系并將其商業化。專注于免疫治療領域,特別是 CAR-T/NK 細胞技術。ProMab 還開發了一種新型的 mRNA 脂質納米顆粒(mRNA-LNP)平臺,用于即用型試劑和定制研究服務,以推進現有產品并擴展到更多的研究領域。

- 注意
-
該頁面的中文產品信息的翻譯,僅供參考。準確的產品信息請以廠家的英文說明書為準。下單前,請瀏覽說明書確認。
-